

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

DNA Repair 2014

13th Biennial Conference of the DGDR (German Society for Research on DNA Repair)

8. – 12. September 2014
University Medical Center Mainz

Topics

- All DNA repair pathways (MGMT, BER, NER, MMR, HR, NHEJ)
- Damage tolerance, TLS
- Regulation of repair genes
- Structure and modification of repair proteins
- Modulation of repair processes by pharmacological inhibitors
- DNA damage response
- DNA damage and cell cycle control
- Repair and aging
- Repair and inflammation
- Repair and carcinogenesis
- Cancer therapy

Conference Fee

Non-members: 300 €

Members: 220 €

Students: 150 €

Abstract submission deadline
and early booking: June 30, 2014

www.dgdr.de

Speakers

K. Borgmann, H. Ulrich
M. Christmann, J. Thomale
C. Reinhardt, S. Emmert
B. Epe, C. Fournier, A. Bürkle
B. Kaina, A. Hartwig, G. Fritz
T. Schwerdtle, F. Rödel
B. Schumacher, G. Iliakis
S. Jentsch, C. Kisker
W. Mansour, H. Pospiech
M. Löbrich, W.P. Roos
A. Ladurner, V. Jendrossek
T. Hofmann, C. Niehrs
H. Puchta, J. Puizina,
Z.Q. Wang and others

Hot topic lecturers

Vilhelm A. Bohr, *Bethesda*
Eugenia Dogliotti, *Rome*
Jan Hoeijmakers, *Rotterdam*
Mats Ljungman, *Ann Arbor*
Leon Mullenders, *Leiden*

Scientific Advisory Committee

A. Bürkle	K. Borgmann	B. Epe
A. Hartwig	M. Löbrich	T. Schwerdtle
J. Thomale	H. Ulrich	L. Wiesmüller
M. Digweed	G. Fritz	F. Grosse

Organization and contact:

Bernd Kaina and coworkers
Institute of Toxicology
University Medical Center
D-55131 Mainz
Tel: +49-(0)6131-17-9357
strauch@uni-mainz.de

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Cryopreservation of Viable Human Lung Tissue for Versatile Post-thaw Analyses and Culture. J.E. BAATZ, D.A. NEWTON, E.C. RIEMER, C.E. DENLINGER, E.E. JONES, R.R. DRAKE, D.D. SPYROPOULOS (*Charleston, SC, USA*)

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models. E. DAUDIGEOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (*Orsay; Villejuif, France*)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (*Heidelberg; Gießen, Germany*)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, M.M. SPRACHMAN, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIMÄKI, M. ESKELINEN, I. ILVES, R. VANNINEN, P. MIETTINEN, H. PAAJANEN (*Kuopio, Finland*)

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (*Tokyo; Yokohama, Japan*)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada*)

Effects of Interactions between Progesterone and Prostaglandin on Uterine Contractility in Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (*Erlangen, Germany*)

Esophageal Radioprotection in Thoracic Irradiated Mice with Transgenic Lung Tumors by Swallowed JP4-039/F15. M.W. EPPERLY, J.P. GOFF, D. FRANICOLA, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (*Munich; Bonn, Germany; Istanbul, Turkey*)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON (*Uppsala, Sweden*)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (*Kyoto, Japan*)

Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. SHEN, T. DUAN, Y.-Y. XU, S.C. KHOR, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (*Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA*)

Anti-inflammatory Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÄTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (*Heidelberg, Germany*)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama; Tokyo, Japan*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online Open Access Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our website www.cgp.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Papers

Genome-wide Transcriptional Sequencing Identifies Novel Mutations in Metabolic Genes in Human Hepatocellular Carcinoma (HCC). D.M. MEERZAMAN, C. YAN, Q.-R. CHEN, M.N. EDMONSON, C.F. SCHAEFER, R.J. CLIFFORD, B.K. DUNN, L. DONG, R.P. FINNEY, C.M. CULTRARO, Y. HU, Z. YANG, C.V. NGUYEN, J.M. KELLEY, S. CAI, H. ZHANG, J. ZHANG, R. WILSON, L. MESSMER, Y.-H. CHUNG, J.A. KIM, N.H. PARK, M.-S. LYU, I.H. SONG, G. KOMATSOULIS, K.H. BUETOW (*Rockville; Bethesda, MD; Memphis, TN, USA; Seoul; Ulsan; Cheon-An, South Korea*)

Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (*Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore*)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHWAITTE (*Austin TX, USA*)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (*Lübeck, Germany*)

Proteomic Analysis of Soft Tissue Tumor Implants Treated with a Novel Polybisphosphonate. A. ALAIYA, J. FOX, S. BOBIS, G. MATIC, Z. SHINWARI, E. BARHOUSH, M. MÁRQUEZ, S. NILSSON, A.R. HOLMBERG (*Riyadh, Saudi Arabia; Manchester, UK; Stockholm, Sweden*)

Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (*Tokyo; Gunma, Japan*)

Review: Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer. U.H. WEIDLE, G. TIEFENTHALER, C. SCHILLER, E.H. WEISS, G. GEORGES, U. BRINKMANN (*Penzberg; Munich, Germany*)

A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (*Boca Raton, FL, USA*)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISSETTY, D.C. MITCHELL, B.A. BRYAN (*El Paso, TX, USA*)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHEER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (*Hamburg; Rostock; Berlin, Germany*)

Serum and Tissue Metabolomics of Head and Neck Cancer. K. YONEZAWA, S. NISHIUMI, J. KITAMOTOMATSUDA, T. FUJITA, K. MORIMOTO, D. YAMASHITA, M. SAITO, N. OTSUKI, Y. IRINO, M. SHINOHARA, M. YOSHIDA, K.-I. NIBU (*Kobe, Japan*)

Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (*Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong*)

Mutational Analysis of Gastrointestinal Stromal Tumors (GISTs): Procedural Approach for Diagnostic Purposes. R. PALMIROTTA, M.L. DE MARCHIS, G. LUDOVICI, B. LEONE, R. COVELLO, S. CONTI, L. COSTARELLI, D. DELLA-MORTE, P. FERRONI, M. ROSELLI, F. GUADAGNI (*Rome, Italy; Miami, FL, USA*)

Subscription Order Form 2014

- Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).
Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2014 online subscriptions include free online access to vol. 24 (2004) - 33 (2013).
- Please send me the following previous volumes (1-33) at 50% discount on the above rates.
- Payment is enclosed. Please invoice.
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

 Tel:
 Fax: e-mail:
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2014 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability. Effective from January to December 2014).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2013
- 33 volumes
- over 108,100 pages
- over 16,000 original articles
- 769 reviews
- over 73,300 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:
 ANTICANCER RESEARCH, International Institute of Anticancer Research,
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2014

- I am one of the authors of the article published in Anticancer Research Vol....., pp., year
- Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) at Euro 195.00 (print) per volume.
- Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address:

 Tel-Fax:
 e-mail:
 Date and signature:

Expression of Chemotaxis- and Angiogenesis-related Factors in Human Monocytes Following Interaction with Colon Cancer Cells Is Suppressed by Low-dose Lipopolysaccharide. T. HONDA, H. INAGAWA, I. YAMAMOTO (<i>Sagamihara, Kanagawa; Kagawa, Japan</i>)	4609
Pre-clinical Study of BK-UM, a Novel Inhibitor of HB-EGF, for Ovarian Cancer Therapy. S.O. NAM, F. YOTSUMOTO, K. MIYATA, Y. SUZAKI, H. YAGI, T. ODAWARA, S. MANABE, T. ISHIKAWA, M. KUROKI, E. MEKADA, S. MIYAMOTO (<i>Fukuoka; Osaka; Kagawa, Japan</i>)	4615
Radiosensitivity Uncertainty Evaluation for the <i>In Vitro</i> Biophysical Modeling of EMT6 Cells. M. OITA, Y. UTO, M. TOMINAGA, M. SASAKI, Y. HARA, T. KISHI, H. HORI (<i>Okayama; Tokushima, Japan</i>) ...	4621
Molecular Analysis of <i>Streptococcus anginosus</i> -derived Saga Peptides. Y. KAWAGUCHI, A. TABATA, H. NAGAMUNE, K. OHKURA (<i>Chiba; Tokushima, Tokushima; Suzuka, Mie, Japan</i>).....	4627
Benefit of Lateral Lymph Node Dissection for Rectal Cancer: Long-term Analysis of 944 Cases Undergoing Surgery at a Single Center (1975-2004). T. KINUGASA, Y. AKAGI, K. SHIROUZU (<i>Fukuoka, Japan</i>) ...	4633

An NDT Study of a Boron Tracedrug UTX-51 for Glycated BSA as an AGE Model. R. TADA, Y. UTO, S.-I. MASUNAGA, Y. KINASHI, K. ONO, H. HORI (<i>Tokushima; Osaka, Japan</i>)	4503
An Epithelial Cell Adhesion Molecule- and CD3-Bispecific Antibody Plus Activated T-Cells Can Eradicate Chemoresistant Cancer Stem-like Pancreatic Carcinoma Cells <i>In Vitro</i> . M. UMEBAYASHI, A. KIYOTA, N. KOYA, H. TANAKA, H. ONISHI, M. KATANO, T. MORISAKI (<i>Fukuoka, Japan</i>)	4509
Investigation on the Reaction Conditions of <i>Staphylococcus aureus</i> Sortase A for Creating Surface-modified Liposomes as a Drug-delivery System Tool. A. TABATA, N. ANYOJI, Y. OHKUBO, T. TOMOYASU, H. NAGAMUNE (<i>Tokushima, Japan</i>)	4521
NKG2D-directed Cytokine-activated Killer Lymphocyte Therapy Combined with Gemcitabine for Patients with Chemoresistant Metastatic Solid Tumors. T. MORISAKI, T. HIRANO, N. KOYA, A. KIYOTA, H. TANAKA, M. UMEBAYASHI, H. ONISHI, M. KATANO (<i>Fukuoka, Japan</i>)	4529
Multicolor Analysis of Cell Surface Marker of Human Leukemia Cell Lines Using Flow Cytometry. T. INOUE, A. SWAIN, Y. NAKANISHI, D. SUGIYAMA (<i>Fukuoka, Japan</i>)	4539
Resveratrol Induces Luminal Apoptosis of Human Colorectal Cancer HCT116 Cells in Three-dimensional Culture. T. TSUNODA, S. ISHIKURA, K. DOI, H. MATSUZAKI, Y. IWAIHARA, S. SHIRASAWA (<i>Fukuoka, Japan</i>).....	4551
A Neutron Dynamic Therapy with a Boron Tracedrug UTX-51 Using a Compact Neutron Generator. H. HORI, R. TADA, Y. UTO, E. NAKATA, T. MORII, K. MASUDA (<i>Tokushima; Uji, Kyoto, Japan</i>)	4557
Dok2 Likely Down-regulates <i>Klf1</i> in Mouse Erythroleukemia Cells. Y. TANAKA, K. KULKEAW, T. INOUE, K.S. TAN, Y. NAKANISHI, S. SHIRASAWA, D. SUGIYAMA (<i>Fukuoka, Japan</i>)	4561
Minichromosome Maintenance Protein 7 Is A Risk Factor for Recurrence in Patients with Dukes C Colorectal Cancer. Y. ISHIBASHI, T. KINUGASA, Y. AKAGI, T. OHCHI, Y. GOTANDA, N. TANAKA, S. FUJINO, K. YUGE, S. KIBE, N. YOSHIDA, T. MIZOBE, Y. OKA, T. YOSHIDA, K. SHIROUZU (<i>Fukuoka, Japan</i>).....	4569
A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line. M. ISHIKAWA, T. INOUE, T. INUI, D. KUCHIIKE, K. KUBO, Y. UTO, T. NISHIKATA (<i>Kobe; Tokushima; Osaka, Japan</i>)	4577
Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos. Y. UTO, D. TAMATANI, Y. MIZUKI, Y. ENDO, I. NAKANISHI, K. OHKUBO, S. FUKUZUMI, M. ISHIZUKA, T. TANAKA, D. KUCHIIKE, K. KUBO, T. INUI, H. HORI (<i>Tokushima; Kanazawa; Chiba; Osaka; Tokyo; Kobe, Japan</i>)	4583
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy. T. INUI, K. MAKITA, H. MIURA, A. MATSUDA, D. KUCHIIKE, K. KUBO, M. METTE, Y. UTO, T. NISHIKATA, H. HORI, N. SAKAMOTO (<i>Tokushima; Osaka; Tokyo; Kobe, Japan</i>)	4589
Efficacy and Safety of Irinotecan Plus S-1 (IRIS) Therapy to Treat Advanced/Recurrent Colorectal Cancer. D. HIGASHI, Y. EGAWA, Y. HIRANO, K. HIRANO, T. MIYAKE, H. TAKAHASHI, S. UWATOKO, S. ABE, S. YAMAMOTO, K. MIKAMI, K. FUTAMI, T. MAEKAWA, R. INOUE, M. MIYAZAKI (<i>Chikushino, Fukuoka, Japan</i>).....	4595
Prospective Evaluation of Safety of Immune-cell Therapy for Patients with Various Types of Advanced Cancer. T. KAMIGAKI, E. MATSUDA, S. OKADA, K. NAITOH, T. KONDO, H. IBE, R. MAEKAWA, S. GOTO (<i>Tokyo, Japan</i>)	4601

Zoledronic Acid Improves Clinical Outcomes in Patients with Bone Metastatic Hormone-naïve Prostate Cancer in a Multicenter Clinical Trial. T. OKEGAWA, M. HIGAKI, T. MATSUMOTO, H. KASE, A. MURATA, K. NODA, H. NODA, H. ASAOKA, M. OSHI, J. TOMOISHI, H. UCHIDA, E. HIGASHIHARA, K. NUTAHARA, BONE METASTASIS PROSTATE CANCER GROUP (<i>Mitaka; Tachikawa; Hachioji; Nishitokyo; Suginami; Nishitokyo; Higashimurayama; Akiruno; Fuchu; Ome; Tokyo, Japan</i>)	4415
Surgical Outcomes of Anatomical Resection for Solitary Recurrent Hepatocellular Carcinoma. Y.-I. YAMASHITA, D. IMAI, Y. BEKKI, K. TAKEISHI, E. TSUJITA, T. IKEGAMI, T. YOSHIZUMI, T. IKEDA, K. SHIRABE, T. ISHIDA, Y. MAEHARA (<i>Hiroshima; Fukuoka, Japan</i>)	4421
Hypothyroidism After Radiotherapy for Primary Thyroid Lymphoma. N. ISHIBASHI, T. MAEBAYASHI, T. AIZAWA, M. SAKAGUCHI, O. ABE, T. SAITO, J. KAWAMORI, Y. TANAKA (<i>Tokyo; Kanagawa, Japan</i>)...	4427
Longitudinal Analysis of Late Vaginal Mucosal Reactions After High-dose-rate Brachytherapy in Patients with Gynecological Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. NARUMI, Y. YOSHIOKA (<i>Takatsuki; Osaka; Suita, Osaka; Kyoto, Japan</i>)	4433
Detection of Thyroid Cancer by an FDG-PET Cancer Screening Program: A Japanese Nationwide Survey. R. MINAMIMOTO, M. SENDA, S. JINNOUCHI, T. TERAUCHI, T. YOSHIDA, T. INOUE (<i>Tokyo; Kobe; Kagoshima; Kurume; Yokohama, Japan</i>)	4439
The Role of Interim ¹⁸ F-FDG PET/CT in Predicting Early Response to Neoadjuvant Chemotherapy in Breast Cancer. K. PAHK, S. RHEE, J. CHO, M. SEO, S. LEE, T. PARK, S. PARK, E. LEE, K.H. PARK, C. KIM, J.S. EO, S. KIM, J.G. CHOE (<i>Seoul; Ansan, South Korea</i>)	4447
Clinical Significance of Urokinase-type Plasminogen Activator (uPA) and its Type-1 Inhibitor (PAI-1) for Metastatic Sentinel Lymph Node Involvement in Breast Cancer. W. HARMS, W. MALTER, S. KRÄMER, U. DREBBER, A. DRZEZGA, M. SCHMIDT (<i>Cologne, Germany</i>)	4457
Clinicopathological Characteristics and Prognosis of Patients According To Recurrence Time After Radical Nephrectomy for Localized Renal Cell Carcinoma: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO). O. BOZKURT, M. İNANC, I. HACİBEKİROĞLU, O. ESBİAH, M. SEKER, A. ULAS, K. AYDIN, M. UYSAL, M. KÜCÜKÖNER, D. UNCU, A. CİLTAS, O.Ü. ÜNAL, A. DURNALI, U. DEMİRCİ, V. BERK, O. TONYALI, B. OKSÜZOĞLU, H. KARACA, M. OZKAN (<i>Kayseri; Trakya; Ankara; Sivas; Istanbul; Afyon; Diyarbakir; Izmir; Elazığ, Turkey</i>)	4463
Prediction of Lymph Node Metastasis in Patients with Submucosa-Invading Early Gastric Cancer. A. SHIDA, S. FUJIOKA, M. KAWAMURA, N. TAKAHASHI, Y. ISHIBASHI, K. NAKADA, N. MITSUMORI, N. OMURA, K. YANAGA (<i>Tokyo, Japan</i>)	4471
Errata	4475
Proceedings of the 17th Annual Meeting of the Society of Biotherapeutic Approaches. Special Issue Edited by M. Kuroki and G.-I. Soma.....	4477
Preface.....	4479
Review: Novel Treatment Strategies for Cancer and Their Tumor-targeting Approaches Using Antibodies Against Tumor-associated Antigens. M. KUROKI, N. SHIRASU (<i>Fukuoka, Japan</i>)	4481
Review: The Roles of ZFAT in Thymocyte Differentiation and Homeostasis of Peripheral Naïve T-Cells. K. DOI, S. ISHIKURA, S. SHIRASAWA (<i>Fukuoka, Japan</i>)	4489
Review: Usefulness of Oral Administration of Lipopolysaccharide for Disease Prevention Through the Induction of Priming in Macrophages. H. INAGAWA, C. KOHCHI, G.-I. SOMA (<i>Takamatsu, Kagawa; Niigata, Niigata, Japan</i>)	4497

Silibinin Administration Improves Hepatic Failure Due to Extensive Liver Infiltration in a Breast Cancer Patient. J. BOSCH-BARRERA, B. COROMINAS-FAJA, E. CUYÀS, B. MARTIN-CASTILLO, J. BRUNET, J.A. MENENDEZ (<i>Girona, Catalonia, Spain</i>).....	4323
Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial. I. YILDIZ, M. EKENEL, T. AKMAN, M. KOCAR, M. UYSAL, M. KANITEZ, U. VAROL, I.V. BAYOGLU, D. TURAL, M.A. KAPLAN, N. AVCI, Z. SÜRMELE, İ. DEDE, A. ULAŞ, O. YAZICI, M. BASARAN (<i>Izmir; Istanbul; Sanliurfa; Afyonkarahisar; Istanbul; Diyarbakir; Balikesir; Ankara; Bursa, Turkey</i>)	4329
Detection and Characterization of Focal Liver Lesions by Split-bolus Multidetector-row CT: Diagnostic Accuracy and Radiation Dose in Oncologic Patients. M. SCIALPI, B. PALUMBO, L. PIEROTTI, S. GRAVANTE, A. PIUNNO, A. REBONATO, A. D'ANDREA, A. REGINELLI, I. PISCIOLI, L. BRUNESE, A. ROTONDO (<i>Perugia; Caserta; Naples; Budrio; Campobasso, Italy</i>)	4335
Surgical Approach and Long-term Clinical Outcome in Women with Microinvasive Cervical Cancer. F. SOPRACORDEVOLLE, G. CHIOSSI, M. BARBERO, P. CRISTOFORONI, B. GHIRINGHELLO, A. FREGA, F. TORTOLANI, F. BOSELLI, N. CLEMENTE, A. CIAVATTINI, ITALIAN SOCIETY OF COLPOSCOPY and CERVICO-VAGINAL PATHOLOGY (SICPCV) (<i>Aviano; Modena; Asti; Genoa; Turin; Rome; Ancona, Italy</i>).....	4345
Biologic Factors Associated with Tumor Oxygenation Are Prognostic in Patients with Stage III Esophageal Cancer: Long-term Results. D. RADES, A. BAJROVIC, S.E. SCHILD, C. THORNS, E. KILIC (<i>Lübeck; Hamburg; Berlin, Germany; Scottsdale, AZ, USA</i>)	4351
Predicting Survival after Whole-Brain Irradiation for Cerebral Metastases from Prostate Cancer. T. BARTSCHT, D. RADES (<i>Lübeck, Germany</i>)	4357
Definitive Extended-field Intensity-modulated Radiotherapy with Chemotherapy for Cervical Cancer with Para-aortic Nodal Metastasis. J. JUNG, G. PARK, Y.S. KIM (<i>Seoul, South Korea</i>)	4361
Usefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus. A. OBA, S. TAKAHASHI, Y. KATO, N. GOTOHDA, T. KINOSHITA, H. SHIBASAKI, M. IKEDA, M. KONISHI (<i>Chiba, Japan</i>)	4367
Age Does Not Worsen the Efficacy Nor Tolerance to Combined Induction Therapies in Locally Advanced Non-small Cell Lung Cancer. D. MARQUEZ-MEDINA, A. MARTIN-MARCO, A. OJANGUREN-GARRANZ (<i>Lleida, Spain</i>)	4373
Primary Diffuse Large B-Cell Lymphoma of the Uterus: Case Report and Review. V.D. MANDATO, R. PALERMO, A. FALBO, I. CAPODANNO, F. CAPODANNO, M.C. GELLI, L. AGUZZOLI, M. ABRATE, G.B. LA SALA (<i>Reggio Emilia, Italy</i>).....	4377
Recurrence Patterns of Esophagogastric Junction Adenocarcinoma According to Siewert's Classification After Radical Resection. Y. HOSOKAWA, T. KINOSHITA, M. KONISHI, S. TAKAHASHI, N. GOTOHDA, Y. KATO, M. HONDA, A. KAITO, H. DAIKO, T. KINOSHITA (<i>Kashiwa, Japan</i>)	4391
Prognostic Impact of Hepatectomy for Patients with Non-hepatitis B, Non-hepatitis C Hepatocellular Carcinoma. T. OCHIAI, S. OGINO, T. ISHIMOTO, A. TOMA, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, E. OTSUJI (<i>Kyoto, Japan</i>)	4399
A Case of Herpes Simplex-associated Encephalitis After Brain Irradiation for Lung Cancer Metastases. A. MATIKAS, E. KONTOPODIS, G. NINTOS, T. BILIDAS, D.P. KOFTERIDIS, E.Z. PAPADAKI, E. LYRARAKI, K. KANATSOULI, D. MAVROUDIS (<i>Heraklion, Greece</i>)	4411

Surgical Treatment of Colorectal Cancer Pulmonary Metastases: 12-year Results. J. VODICKA, V. SPIDLEN, V. TRESKA, J. FICHTL, V. SIMANEK, J. SAFRANEK, S. VEJVODOVA, P. MUKENSNABL, O. TOPOLCAN (<i>Pilsen, Czech Republic</i>)	4239
Postoperative Radiation Therapy for Parotid Pleomorphic Adenoma with Close or Positive Margins: Treatment Outcomes and Toxicities. S. PATEL, W.F. MOURAD, C. WANG, B. DHANIREDDY, C. CONCERT, M. RYNIAK, A.S. KHORSANDI, R.A. SHOURBAJI, Z. LI, B. CULLINEY, R. PATEL, R.L. BAKST, T. TRAN, D. SHASHA, S. SCHANTZ, M.S. PERSKY, K.S. HU, L.B. HARRISON (<i>New York; Bronx, NY, USA; Guangzhou, China</i>)	4247
Seminoma Patients Treated at a Minor Oncological Department During 1986-2010: Treatment and Outcome. H.S. HAUGNES, Ø. SOLHAUG, J. STENBERG, L.V. HJELLE, R.M. BREMNES (<i>Tromsø,; Leknes; Stokmarknes, Norway</i>)	4253
Feasibility of Simultaneous Integrated Boost IMRT (SIB-IMRT) for Castration-Resistant Prostate Cancer. T. HAKARIYA, S. OBATA, T. IGAWA, H. SAKAI (<i>Nagasaki, Japan</i>)	4261
Macroscopic Type Is a Prognostic Factor for Recurrence-free Survival After Resection of Gastric GIST. H. MIYAMOTO, C. KUNISAKI, Y. OTSUKA, M. TAKAHASHI, R. TAKAGAWA, K. MISUTA, K. KAMEDA, H. MAKINO, G. MATSUDA, N. YAMAGUCHI, N. KAMIYA, T. MURAKAMI, S. MORITA, H. AKIYAMA, I. ENDO (<i>Yokohama; Tokyo; Fujisawa; Yokosuka; Ito, Japan</i>)	4267
Immunohistochemical Features Associated with Sensitivity to Lapatinib plus Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer. Y. CHA, S.-W. HAN, H. SEOL, D.-Y. OH, S.-A. IM, Y.-J. BANG, I.A. PARK, W. HAN, D.-Y. NOH, T.-Y. KIM (<i>Seoul; Suwon, South Korea</i>)	4275
Radio-chemotherapy with Temozolomide in Elderly Patients with Glioblastoma. A Mono-institutional Experience. F. PASQUALETTI, P. FERRAZZA, P. COCUZZA, L. FATIGANTE, G. PASQUALETTI, M.G. FABBRINI, F. MONZANI (<i>Pisa, Italy</i>)	4281
Elderly Woman with Triple-negative Metastatic Breast Cancer Successfully Treated with Metronomic Capecitabine. F. DE IULIIS, G. SALERNO, L. TAGLIERI, R. VICINANZA, R. LANZA, S. SCARPA (<i>Rome, Italy</i>)	4287
Postoperative Functional Evaluation of Gastric Tube After Laparoscopic Proximal Gastrectomy for Gastric Cancer. E. MOCHIKI, M. FUKUCHI, K. OGATA, T. OHNO, H. ISHIDA, H. KUWANO (<i>Saitama; Gunma, Japan</i>)	4293
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement. S. PARK, B. HAN, K. KIM, S.J. KIM, J.H. JANG, W.S. KIM, C.W. JUNG (<i>Seoul; Anyang, South Korea</i>)	4299
Living Donor Liver Transplantation Followed by Total Gastrectomy – A Two-stage Planned Operative Strategy for Early Gastric Cancer Concomitant with Decompensated Liver Cirrhosis. S. NISHIMURA, H. SAEKI, T. IKEGAMI, K. ANDO, Y.-I. YAMASHITA, E. OKI, T. YOSHIZUMI, M. MORITA, K. SHIRABE, Y. MAEHARA (<i>Fukuoka, Japan</i>)	4307
Treatment Sequence of Aromatase Inhibitors and Radiotherapy and Long-term Outcomes of Breast Cancer Patients. M. ISHITOBI, M. SHIBA, T. NAKAYAMA, K. MOTOMURA, H. KOYAMA, K. NISHIYAMA, Y. TAMAKI (<i>Osaka, Japan</i>)	4311
No Infectious Hepatic Complications Following Radioembolization with ⁹⁰ Y Microspheres in Patients with Biliodigestive Anastomosis. D. GEISEL, M.-J. POWERSKI, D. SCHNAPAUFF, F. COLLETTINI, R. THIEL, T. DENECKE, G. WIENERS, B. GEBAUER (<i>Berlin, Germany</i>)	4315

Mechanisms of Action of 17βH-neriifolin on its Anticancer Effect in SKOV-3 Ovarian Cancer Cell Line. S.S. MOHD MUTALIP, N.M. YUNOS, P.S. ABDUL-RAHMAN, M.H. JAURI, A. OSMAN, M.I. ADENAN (<i>Selangor; Kuala Lumpur, Malaysia</i>)	4141
Comparative Analysis of Hsp10 and Hsp90 Expression in Healthy Mucosa and Adenocarcinoma of the Large Bowel. F. RAPPA, C. SCIUME, M. LO BELLO, C.C. BAVISOTTO, A.M. GAMMAZZA, R. BARONE, C. CAMPANELLA, S. DAVID, F. CARINI, F. ZARCONI, S. RIZZUTO, A. LENA, G. TOMASELLO, M.L. UZZO, G.F. SPATOLA, G. BONAVENTURA, A. LEONE, A. GERBINO, F. CAPPELLO, F. BUCCHIERI, G. ZUMMO, F. FARINA (<i>Palermo, Italy</i>)	4153
α-Phellandrene Alters Expression of Genes Associated with DNA Damage, Cell Cycle, and Apoptosis in Murine Leukemia WEHI-3 Cells. J.-J. LIN, C.-C. YU, K.-W. LU, S.-J. CHANG, F.-S. YU, C.-L. LIAO, J.-G. LIN, J.-G. CHUNG (<i>Taichung, Taiwan, ROC</i>)	4161
<i>Clinical Studies</i>	
Claudins as Prognostic Factors for Renal Cell Cancer. J. VIRMAN, Y. SOINI, P. KUJALA, T. LUUKKAALA, T. SALMINEN, K. SUNELA, P.-L. KELLOKUMPU-LEHTINEN (<i>Tampere; Kuopio, Finland</i>)	4181
Dose-escalated Radiation Therapy With and Without Short-course Androgen Deprivation for Intermediate-risk Prostate Cancer. D. SCHREIBER, J. RINEER, A. SURAPANENI, E. NAVO, M. AGARWAL, E. NWOKEDE, M. ROTMAN, D. SCHWARTZ (<i>New York; Brooklyn, NY; Orlando, FL, USA</i>).....	4189
Effects of Chemoradiotherapy on Lymph Nodes in Patients with Rectal Adenocarcinoma: Evaluation of Numbers and Sizes of Retrieved Lymph Nodes Inside and Outside the Radiation Field. K. OKADA, S. SADAHIRO, T. SUZUKI, A. TANAKA, G. SAITO, A. KAMIJO, T. AKIBA, S. KAWADA (<i>Kanagawa, Japan</i>)	4195
Predictive Biomarkers for the Outcome of Vaccination of Five Therapeutic Epitope Peptides for Colorectal Cancer. S. HAZAMA, H. TAKENOUCHE, R. TSUNEDOMI, M. IIDA, N. SUZUKI, N. IIZUKA, Y. INOUE, K. SAKAMOTO, M. NAKAO, Y. SHINDO, S. KANEKIYO, Y. TOKUMITSU, K. YOSHIMURA, N. MAEDA, K. MAEDA, Y. MAEDA, H. MATSUI, S. YOSHINO, Y. NAKAMURA, Y. FUJITA, Y. HAMAMOTO, M. OKAMOTO, T. FUJITA, Y. KAWAKAMI, M. OKA (<i>Ube, Yamaguchi; Tokyo, Japan; Chicago, IL, USA</i>)	4201
Significance of Accurate Human Epidermal Growth Factor Receptor-2 (HER2) Evaluation as a New Biomarker in Gastric Cancer. Y. KIMURA, E. OKI, A. YOSHIDA, S. AISHIMA, Y. ZAITSU, H. OHTSU, K. ANDO, S. IDA, H. SAEKI, M. MORITA, T. KUSUMOTO, Y. ODA, Y. MAEHARA (<i>Fukuoka, Japan</i>)	4207
Management of Peripheral Neuropathy Induced by Nab-Paclitaxel Treatment for Breast Cancer. T. OHNO, T. MINE, H. YOSHIOKA, M. KOSAKA, S. MATSUDA, M. DE KERCKHOVE, C. DE KERCKHOVE, J. IRIE, K. INOUE, M. HARAGUCHI, M. KITAJIMA, I. SHINICHIRO, H. TOKAI, T. TANAKA, R. IZUMIDA (<i>Nagasaki, Japan</i>)	4213
Expression of Stathmin1 in Gastric Adenocarcinoma. B.-E. BATSAIKHAN, K. YOSHIKAWA, N. KURITA, T. IWATA, C. TAKASU, H. KASHIHARA, M. SHIMADA (<i>Tokushima, Japan</i>)	4217
Prognostic Nutritional Index is Associated with Survival After Total Gastrectomy for Patients with Gastric Cancer. M. ISHIZUKA, Y. OYAMA, A. ABE, K. TAGO, G. TANAKA, K. KUBOTA (<i>Mibu, Tochigi, Japan</i>)	4223
Efficacy of Transarterial Chemoembolization Targeting Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma. A. TAWADA, T. CHIBA, Y. OOKA, N. KANOGAWA, T. MOTOYAMA, T. SAITO, S. OGASAWARA, E. SUZUKI, H. MARUYAMA, F. KANAI, M. YOSHIKAWA, O. YOKOSUKA (<i>Chiba, Japan</i>)	4231

SOX18 Expression Predicts Response to Platinum-based Chemotherapy in Ovarian Cancer. B. PULA, C. KOBIERZYCKI, D. SOLINSKI, M. OLBROMSKI, E. NOWAK-MARKWITZ, M. SPACZYNSKI, W. KEDZIA, M. ZABEL, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>).....	4029
Dehydroepiandrosterone Inhibits Proliferation and Suppresses Migration of Human Cervical Cancer Cell Lines. Y.N. ORTEGA-CALDERÓN, R. LÓPEZ-MARURE (<i>México City, México</i>).....	4039
A Tertiary Sulfonium Compound, Dimethylsulfoniopropionate in Green Sea Algae, Completely Suppresses Crucial Ehrlich Ascites Carcinoma in Mice. K. NAKAJIMA, S. TSUJIWAKI, Y. NAKAJIMA (<i>Takarazuka, Hyogo; Okayama, Japan</i>).....	4045
Can Expression of CXCL12 and CXCR4 Be Used to Predict Survival of Gastric Cancer Patients? H. SATOMURA, K. SASAKI, M. NAKAJIMA, S. YAMAGUCHI, S. ONODERA, K. OTSUKA, M. TAKAHASHI, H. MUROI, Y. SHIDA, H. OGATA, K. OKAMOTO, H. KATO (<i>Mibu, Tochigi, Japan</i>).....	4051
Expression of Nogo Isoforms and Nogo-B Receptor (NgBR) in Non-small Cell Lung Carcinomas. B. PULA, B. WERYNSKA, M. OLBROMSKI, B. MUSZCZYNSKA-BERNHARD, M. CHABOWSKI, D. JANCZAK, M. ZABEL, M. PODHORSKA-OKOLOW, P. DZIEGIEL (<i>Wroclaw; Poznan, Poland</i>).....	4059
Silencing of Phosphoinositide-specific Phospholipase C ϵ Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines. V.R. LO VASCO, M. LEOPIZZI, D. STOPPOLONI, C. DELLA ROCCA (<i>Rome, Italy</i>).....	4069
Evaluating the Cytotoxic Effects of Novel Quinone Compounds. M. SAIBU, S. SAGAR, I. GREEN, F. AMEER, M. MEYER (<i>Bellville, South Africa</i>).....	4077
Anticancer Activity of Hispidin <i>via</i> Reactive Oxygen Species-mediated Apoptosis in Colon Cancer Cells. J.-H. LIM, Y.-M. LEE, S.R. PARK, D.H. KIM, B.O. LIM (<i>Chungju, South Korea</i>).....	4087
High Oxygen Partial Pressure Increases Photodynamic Effect on HeLa Cell Lines in the Presence of Chloraluminium Phtalocyanine. R. BAJGAR, H. KOLAROVA, L. BOLEK, S. BINDER, K. PIZOVA, A. HANAKOVA (<i>Olomouc; Plzen, Czech Republic</i>).....	4095
Targeting the Wnt/Beta-Catenin Pathway in Renal Cell Carcinoma. S.A. VON SCHULZ-HAUSMANN, L.C. SCHMEEL, F.C. SCHMEEL, I.G.H. SCHMIDT-WOLF (<i>Bonn, Germany</i>).....	4101
Evaluation of the Contribution of Methylenetetrahydrofolate Reductase Genotypes to Taiwan Breast Cancer. C.-Y. HUANG, W.-S. CHANG, H.-A. SHUI, Y.-H. HSIEH, C.-H. LOH, H.-C. WANG, H.-X. JI, C.-L. HSIAO, C.-M. HSU, C.-W. TSAI, D.-T. BAU (<i>Taipei; Taichung, Taiwan, ROC</i>).....	4109
Search of New Cytotoxic Crude Materials Against Human Oral Squamous Cell Carcinoma Using ¹ H NMR-based Metabolomics. R. SUZUKI, S. MATSUNO, H. SAKAGAMI, Y. OKADA, Y. SHIRATAKI (<i>Saitama; Tokyo, Japan</i>).....	4117
Serum Vimentin Methylation as a Potential Marker for Colorectal Cancer. A. SHIRAHATA, K. HIBI (<i>Yokohama Japan</i>).....	4121
Metformin Inhibits Tumor Cell Migration <i>via</i> Down-regulation of MMP9 in Tamoxifen-resistant Breast Cancer Cells. S.Y. JANG, A. KIM, J.K. KIM, C. KIM, Y.-H. CHO, J.-H. KIM, C.H. KIM, J.-Y. LEE (<i>Seoul, South Korea</i>).....	4127
Semi-synthesis of Nitrogen Derivatives of Oleanolic Acid and Effect on Breast Carcinoma MCF-7 Cells. O.O. OYEDEJI, F.O. SHODE, A.O. OYEDEJI, S.P. SONGCA, E.T. GWEBU, G.M. HILL, W.N. SETZER (<i>Alice; KwaDlangezwa; Mthatha, South Africa; Elizabeth City, NC; Huntsville, AL, USA</i>).....	4135

Tumor Regression by CD4 T-Cells Primed with Dendritic/Tumor Fusion Cell Vaccines. S. KOIDO, Y. ENOMOTO, V. APOSTOLOPOULOS, J. GONG (<i>Chiba; Tokyo, Japan; Melbourne, VIC, Australia; Boston, MA, USA</i>)	3917
Optimal Production of a Fusion Protein Consisting of a Single-chain Variable Fragment Antibody Against a Tumor-associated Antigen and Interleukin-2 in Fed-batch Culture of <i>Pichia pastoris</i> . S. ANULEEJUN, T. PALAGA, Y. KATAKURA, MOTOMU KUROKI, MASAHIDE KUROKI, S.C. NAPATHORN (<i>Bangkok, Thailand; Suita; Fukuoka, Japan</i>)	3925
High Expression of Fusion Proteins Consisting of a Single-chain Variable Fragment Antibody Against a Tumor-associated Antigen and Interleukin-2 in <i>Escherichia coli</i> . S.C. NAPATHORN, MOTOMU KUROKI, MASAHIDE KUROKI (<i>Bangkok, Thailand; Fukuoka, Japan</i>)	3937
Random Migration Contributes to Cytotoxicity of Activated CD8+ T-Lymphocytes But Not NK cells. H. ONISHI, A. KIYOTA, N. KOYA, H. TANAKA, M. UMEBAYASHI, M. KATANO, T. MORISAKI (<i>Fukuoka, Japan</i>)	3947
Prognostic MicroRNA Expression Signature from Examination of Colorectal Primary and Metastatic Tumors. C. ELLERMEIER, S. VANG, K. CLEVELAND, W. DURAND, M.B. RESNICK, A.S. BRODSKY (<i>Providence, RI, USA</i>)	3957
Nuclear Expression of Phosphorylated Focal Adhesion Kinase Is Associated with Poor Prognosis in Human Colorectal Cancer. A. ALBASRI, W. FADHIL, J.H. SCHOLEFIELD, L.G. DURRANT, M. ILYAS (<i>Nottingham, UK; Medina, Saudi Arabia</i>)	3969
Potential of Natural Killer Cell Activity with Myricetin. C. LINDQVIST, M. BOBROWSKA-HÄGERSTRAND, L. MRÓWCZYŃSKA, C. ENGBLOM, H. HÄGERSTRAND (<i>Turku, Finland; Poznań, Poland</i>)	3975
Anti-tumor Effect of Novel Cationic Biomaterials in Prostate Cancer. G. GAKHAR, H. LIU, R. SHEN, D. SCHERR, D. WU, D. NANUS, C.-C. CHU (<i>New York; Ithaca, NY, USA</i>)	3981
Extracellular Matrix of Galectin-1-exposed Dermal and Tumor-associated Fibroblasts Favors Growth of Human Umbilical Vein Endothelial Cells <i>In Vitro</i> : A Short Report. V. PERŽELOVÁ, L. VARINSKÁ, B. DVOŘÁNKOVÁ, P. SZABO, P. SPURNÝ, J. VALACH, J. MOJŽIŠ, S. ANDRÉ, H.-J. GABIUS, K. SMETANA JR., P. GÁL (<i>Košice; Bratislava, Slovak Republic; Prague, Czech Republic; Munich, Germany</i>)	3991
Expression of Somatostatin Type-2 and -4 Receptor and Correlation with Histological Type in Breast Cancer. A. FRATI, R. ROUZIER, B. LESIEUR, G. WERKOFF, M. ANTOINE, A. RODENAS, E. DARAI, E. CHEREAU (<i>Paris; Marseille, France</i>)	3997
Histological Groups of Human Postpubertal Testicular Germ Cell Tumours Harbour Different Genetic Alterations. T. VLADUŠIĆ, R. HRAŠĆAN, B. KRUŠLIN, N. PEĆINA-ŠLAUS, K. PERICA, A. BIĆANIĆ, I. VRHOVAC, M. GAMULIN, J. FRANEKIĆ (<i>Zagreb, Croatia</i>)	4005
Novel Piperazinediones as Antitumor Agents. C.-L. WANG, O. LEE, G. HSIAO, J.-F. LIAN, Y.-W. CHENG (<i>Taiwan; Hsinchu; Taoyuan, Taiwan, ROC</i>)	4013
Activation of the Leukemia Plasmacytoid Dendritic Cell Line PMDC05 by Toho-1, a Novel IDO Inhibitor. A. YAMAHIRA, M. NARITA, M. IWABUCHI, T. UCHIYAMA, S. IWAYA, R. OHIWA, Y. NISHIZAWA, T. SUZUKI, Y. YOKOYAMA, S. HASHIMOTO, J. TAKIZAWA, H. SONE, M. TAKAHASHI (<i>Niigata; Chiba; Nagaoka, Japan</i>)	4021